Overproduction of IGF-2 drives a subset of colorectal cancer cells, which specifically respond to an anti-IGF therapeutic antibody and combination therapies-Reference-Cited by-同舟云学术

Overproduction of IGF-2 drives a subset of colorectal cancer cells, which specifically respond to an anti-IGF therapeutic antibody and combination therapies

Published:2016-07-11 Issue:6 Volume:36 Page:797-806
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Zhong H,Fazenbaker C,Chen C,Breen S,Huang J,Yao X,Ren P,Yao Y,Herbst R,Hollingsworth R E

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

https://www.nature.com/articles/onc2016248.pdf

Reference47 articles.

1. Siegel R, Ma J, Zou Z, Jemal A . Colorectal cancer statistics. 2014. CA Cancer J Clin 2014; 64: 104–117.

2. Saltz LB, Meropol NJ, Loehrer Sr PJ, Needle MN, Kopit J, Mayer RJ . Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201–1208.

3. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlesz A, Neyns B et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658–1664.

4. Fearon ER . Molecular genetics of colorectal cancer. Ann Rev Pathol 2011; 6: 467–507.

5. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330–337.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In Silico Approach to Molecular Profiling of the Transition from Ovarian Epithelial Cells to Low-Grade Serous Ovarian Tumors for Targeted Therapeutic Insights;Current Issues in Molecular Biology;2024-02-26

2. Insulin receptor alternative splicing in breast and prostate cancer;Cancer Cell International;2024-02-08

3. IGF2BP3 promotes the progression of colorectal cancer and mediates cetuximab resistance by stabilizing EGFR mRNA in an m6A-dependent manner;Cell Death & Disease;2023-09-01

4. The oncogenic function of PLAGL2 is mediated via ASCL2 and IGF2 and a Wnt-independent mechanism in colorectal cancer;American Journal of Physiology-Gastrointestinal and Liver Physiology;2023-08-01

5. The pathological role of C-X-C chemokine receptor type 4 (CXCR4) in colorectal cancer (CRC) progression; special focus on molecular mechanisms and possible therapeutics;Pathology - Research and Practice;2023-08